Results 1 to 10 of about 9,527 (221)

Effects of febuxostat on markers of endothelial dysfunction and renal progression in patients with chronic kidney disease [PDF]

Scientific Reports, 2023
Hyperuricemia relates to chronic kidney disease (CKD) progression and impaired endothelial function. Febuxostat is potent and effective for decreasing serum uric acid levels.
Naowanit Nata, Nanthawut Ninwisut, Pitchamon Inkong, Ouppatham Supasyndh, Bancha Satirapoj   +4 more
doaj   +2 more sources

High-Throughput mRNA Sequencing Reveals Potential Therapeutic Targets of Febuxostat in Secondary Injury After Intracerebral Hemorrhage

Frontiers in Pharmacology, 2022
Febuxostat is a urate-lowering medication for the treatment of patients with gout. This study was performed to elucidate the effects and underlying mechanisms of febuxostat on neuronal injury induced by intracerebral hemorrhage (ICH) in mice. The results
Xueyan Wang, Chenyu Zhang, Chenyu Zhang, Yuwen Li, Yuwen Li, Ting Xu, Ting Xu, Jin Xiang, Yang Bai, Ying Zhang, Qi Wang, Tiejun Zhang, Linchuan Liao   +12 more
doaj   +2 more sources

Safety and efficacy of SHR4640 combined with febuxostat for primary hyperuricemia: a multicenter, randomized, double-blind, phase II study

Therapeutic Advances in Musculoskeletal Disease, 2022
Background: To evaluate the safety, tolerability, and efficacy of SHR4640, a highly selective urate transporter-1 inhibitor, in combination with febuxostat, in patients with primary hyperuricemia.
Honghu Tang, Beibei Cui, Yiyu Chen, Lin Chen, Zhihong Wang, Ning Zhang, Yanlan Yang, Xiaodong Wang, Xiangliang Xie, Lingyun Sun, Wantai Dang, Xianyang Wang, Runzi Li, Jianjun Zou, Yi Zhao, Yi Liu   +15 more
doaj   +2 more sources

Febuxostat [PDF]

Reactions Weekly, 2018
Wittkoepper, Katrin, Emons, J., El-Armouche, Ali   +2 more
core   +9 more sources

A single-centre experience of febuxostat as a second-line urate-lowering therapy [PDF]

Malaysian Family Physician, 2021
Introduction: The purpose of this study was to describe the local experience in terms of drug efficacy and safety using a new xanthine oxidase inhibitor, febuxostat, as a second-line urate-lowering therapy (ULT) in gout patients with normal renal ...
Swee Gaik Ong, Hui Jen Ding
doaj   +1 more source

The Impact of Label Changes (Boxed Warning) on Real-World Febuxostat Utilization in Patients with Gout: A Cross-Sectional Drug Utilization Study

Rheumatology and Therapy, 2023
Introduction This drug utilization study evaluated the impact of 2019 label changes on real-world febuxostat utilization among patients with gout. We describe the numbers and proportions of patients initiating febuxostat as new users (allopurinol-naïve ...
Alexandra Z. Sosinsky, Yufei Song, Lhanoo Gunawardhana, Syd Phillips, Matt Page   +4 more
doaj   +1 more source

Effect of Febuxostat versus Allopurinol on the Glomerular Filtration Rate and Hyperuricemia in Patients with Chronic Kidney Disease

Saudi Journal of Kidney Diseases and Transplantation, 2023
Hyperuricemia is a risk factor for the progression of chronic kidney disease (CKD). We compared febuxostat versus allopurinol in the progression of CKD and hyperuricemia in 101 patients with Stage 3–4 CKD treated with febuxostat or allopurinol for at ...
Shankar Prasad Nagaraju, Srinivas Vinayak Shenoy, Indu Rao, Ravindra Attur Prabhu, Dharshan Rangaswamy, Mohan V. Bhojaraja, Vasudeva Guddattu   +6 more
doaj   +1 more source

Acute effects of hypouricemia on endothelium, oxidative stress, and arterial stiffness: A randomized, double‐blind, crossover study

Physiological Reports, 2021
We hypothesized acute moderate and drastic reductions in uric acid concentration exert different effects on arterial function in healthy normotensive and hypertensive adults.
Benjamin De Becker, Emeline Hupkens, Laurence Dewachter, Catherine Coremans, Cédric Delporte, Pierre van Antwerpen, Thierry Franck, Karim Zouaoui Boudjeltia, Pierre Cullus, Philippe van deBorne   +9 more
doaj   +1 more source

Astragaloside IV improves the pharmacokinetics of febuxostat in rats with hyperuricemic nephropathy by regulating urea metabolism in gut microbiota

Frontiers in Pharmacology, 2022
Hyperuricemic nephropathy (HN) is a common clinical complication of hyperuricemia. The pathogenesis of HN is directly related to urea metabolism in the gut microbiota.
Zhen Xiong Zhao, Xiao Hui Tang, Sheng Lu Jiang, Jia Qian Pang, Yu Bin Xu, Dan Dan Yuan, Ling Ling Zhang, Hui Min Liu, Qing Fan   +8 more
doaj   +1 more source

Febuxostat ameliorates secondary progressive experimental autoimmune encephalomyelitis by restoring mitochondrial energy production in a GOT2-dependent manner. [PDF]

PLoS ONE, 2017
Oxidative stress and mitochondrial dysfunction are important determinants of neurodegeneration in secondary progressive multiple sclerosis (SPMS). We previously showed that febuxostat, a xanthine oxidase inhibitor, ameliorated both relapsing-remitting ...
Josephe A Honorat, Yuji Nakatsuji, Mikito Shimizu, Makoto Kinoshita, Hisae Sumi-Akamaru, Tsutomu Sasaki, Kazushiro Takata, Toru Koda, Akiko Namba, Kazuya Yamashita, Eri Sanda, Manabu Sakaguchi, Atsushi Kumanogoh, Takashi Shirakura, Mizuho Tamura, Saburo Sakoda, Hideki Mochizuki, Tatsusada Okuno   +17 more
doaj   +1 more source